BioStrand to receive an up front of $500,000 & will be eligible to receive future success-based development & clinical milestones along with royalties, following the successful Ab discovery. The companies collaborated on the design, discovery, and development of anti-cancer Abs
The collaboration will utilize BioStrand’s LENSai software (developed from IPA’s HYFT Universal Fingerprint technologies) for in silico Ab discovery to develop clinical molecules
The collaboration combines BioStrand’s revolutionary AI-powered technology & its cutting-edge protein engineering platform for the discovery of potent anti-cancer therapies & will complement BriaCell’s current immunotherapy pipeline for innovative anti-cancer therapies
Ref: Businesswire | Image: IPA
